Cheaper breast cancer drug copy put to the test – but trial ends early
Disease control
Terminated
This phase 3 study tested a biosimilar called PERT-IJS against the original drug Perjeta, both given with standard chemotherapy, in women with early or locally advanced HER2-positive breast cancer. The goal was to see if the biosimilar works just as well at eliminating cancer bef…
Phase: PHASE3 • Sponsor: Biocon Biologics UK Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC